Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.16 USD
Change Today -0.0031 / -1.96%
Volume 6.0K
CAPS On Other Exchanges
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

capstone therapeutics corp (CAPS) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/11/14 - $0.39
52 Week Low
04/22/15 - $0.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

capstone therapeutics corp (CAPS) Related Businessweek News

No Related Businessweek News Found

capstone therapeutics corp (CAPS) Details

Capstone Therapeutics Corp., a biotechnology company, focuses on developing a pipeline of peptides and other molecules for helping patients with under-served medical conditions. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that play an important role in lipoprotein metabolism, which have competed Phase Ia and Phase 1b/2a clinical trials. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

2 Employees
Last Reported Date: 03/16/15
Founded in 1987

capstone therapeutics corp (CAPS) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $100.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $135.0K
Chief Medical Officer
Total Annual Compensation: $135.0K
Compensation as of Fiscal Year 2014.

capstone therapeutics corp (CAPS) Key Developments

Capstone Therapeutics Corp. Proposes to Amend Certificate of Incorporation

Capstone Therapeutics Corp. proposed to amend the company's amended and restated certificate of incorporation to increase the number of authorized shares of common stock from 100,000,000 to 150,000,000, at the AGM to be held on June 19, 2015.

Capstone Therapeutics Corp. - Shareholder/Analyst Call

Capstone Therapeutics Corp. - Shareholder/Analyst Call

Capstone Therapeutics Corp. Auditor Raises 'Going Concern' Doubt

Capstone Therapeutics Corp. filed its 10-K on Mar 16, 2015 for the period ending Dec 31, 2014. In this report its auditor, Moss Adams LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CAPS:US $0.16 USD -0.0031

CAPS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CAPS.
View Industry Companies

Industry Analysis


Industry Average

Valuation CAPS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAPSTONE THERAPEUTICS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at